Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus Toripalimab with or without TP neoadjuvant chemotherapy in locally advanced head and neck squamous cell carcinoma
ChiCTR2400094333Phase 2Not yet recruiting
- Sponsor
- Shandong Second Provincial General Hospital
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nimotuzumab and toripalimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Shandong Second Provincial General Hospital. Primary endpoint: Overall response rate of tumors. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
nimotuzumabtoripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2400094333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094333.